病例报告:慢性脏疾病的贫血患者中Roxadustat过量服用:超出微不足道后果的洞察力
Long-Guang Zhang1, Xue-Juan Ma1, Xiang-Yang Li1
1Department of Nephrology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Frontiers in nephrology
|August 19, 2024
概括
一名患有慢性病 (CKD) 的患者不小心服用了高剂量抗贫血药物罗沙杜沙特 (ROXA),但没有出现不良反应. 这个案例突出了ROXA的重点.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 一名71岁的男性有高血压和功能障碍史,因贫血而接受了roxadustat (ROXA) 的治疗.
- 患者的血红蛋白水平在降低,尽管补充铁.
- 他估计的膜过率 (eGFR) 为每1.73m2.2的32.8毫升/分钟.
研究的目的:
- 报告患有慢性脏病 (CKD) 的患者意外过量服用roxadustat的病例.
- 为了评估roxadustat在超治疗剂量的安全性和耐受性.
- 提供roxadustat的机制,新陈代谢和副作用概况的概述.
主要方法:
- 一名患有CKD的患者错误地服用了roxadustat的1,050 mg/周,而不是处方的150 mg/周,持续了一个月.
- 监测了包括血清肌素 (SCr),血红蛋白 (Hb) 和肝功能测试在内的临床参数.
- 观察了患者对罗沙杜沙特过量剂的反应以及随后以正确剂量重新开始治疗.
主要成果:
- 患者在服用高剂量罗沙沙沙特的一个月内没有报告明显的不适.
- 在过量服用期间,血红蛋白水平从96 g/L显著增加到163 g/L.
- 过量服用期间血清肌素保持稳定,肝酶保持在正常范围内,尽管胆红素暂时升高.
结论:
- 意外摄入显著更高剂量的roxadustat并没有导致这种CKD患者明显的不良事件.
- 用推剂量重新开始使用罗沙沙斯塔特是无事件的,这表明潜在的安全边际.
- 这一案例提供了关于roxadustat在慢性病患者的安全性概况的见解,需要进一步调查其治疗窗口和不良事件的风险因素.
相关概念视频
01:11Renal Failure: Dose Adjustments
71
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
71
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:17Factors Affecting Renal Clearance: Renal Impairment
63
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
63
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:27Dialysis
278
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
278
01:28Renal Drug Excretion: Tubular Secretion
154
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
154